Patent: 9,028,800

Summary for Patent: 9,028,800

Title:	Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
Abstract:	The present application discloses compositions and methods of synthesis and use of .sup.18F or .sup.19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the .sup.18F or .sup.19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the .sup.18F or .sup.19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.
Inventor(s):	D\'Souza; Christopher A. (Pomona, NY), McBride; William J. (Boonton, NJ), Goldenberg; David M. (Mendham, NJ)
Assignee:	Immunomedics, Inc. (Morris Plains, NJ)
Application Number:	14/273,163
Patent Claims:	see list of patent claims

Details for Patent 9,028,800

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Centocor Ortho Biotech Products, L.p.	ORTHOCLONE OKT3	muromanab-cd3	Injection	103463	09/14/1992		2027-01-11
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2027-01-11
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2027-01-11
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2027-01-11
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2027-01-11
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2027-01-11